



University of Groningen

Letter Regarding "Association Between CKD, Obesity, Cardiometabolic Risk Factors, and Severe COVID-19 Outcomes"

Volbeda, Meint; Jou-Valencia, Daniela; van den Heuvel, Marius; Moser, Jill; van Meurs, Matijs; Franssen, Casper F M

Published in: Kidney International Reports

DOI:

10.1016/j.ekir.2023.04.032

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date: 2023

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Volbeda, M., Jou-Valencia, D., van den Heuvel, M., Moser, J., van Meurs, M., & Franssen, C. F. M. (2023). Letter Regarding "Association Between CKD, Obesity, Cardiometabolic Risk Factors, and Severe COVID-19 Outcomes". *Kidney International Reports*, *8*(9), 1899-1900. https://doi.org/10.1016/j.ekir.2023.04.032

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.



Letter Regarding "Association Between CKD, Obesity, Cardiometabolic Risk Factors, and Severe COVID-19 Outcomes"



To the Editor: In the 2023 April issue of KI Reports, Sorling et al. reported that chronic kidney disease (CKD) is a critical risk factor for severe COVID-19 and death. We would like to further emphasize the negative impact of CKD on outcome in patients with a severe COVID-19 course by showing that preexisting CKD is often not diagnosed in these patients. CKD is underrecognized in the general population because only the more severe CKD stages lead to clinical symptoms. In hospitalized patients, baseline serum creatinine levels are often unknown and elevated creatinine levels are usually interpreted as a sign of acute kidney injury, whereas at least part of the supposedly acutely impaired renal function may in fact be due to preexisting CKD. In addition, pre-existing CKD might be missed in patients with anuric acute kidney injury because albuminuria cannot be assessed. Moreover, a normal estimated glomerular filtration rate and the absence of albuminuria do not rule out histopathological kidney damage, because renal functional reserve can be large enough to avoid a significant rise in serum creatinine.2

We recently reviewed the renal histopathological findings of patients with COVID-19 at an individual patient level from various published studies to increase our understanding of acute kidney injury in COVID-19.3 This allowed us to investigate the incidence of CKD based on renal histology in hospitalized patients with COVID-19. We analyzed the individual patient characteristics including data on the presence or absence of CKD in medical history and post-mortem renal biopsy results from 88 patients with COVID-19 from 8 studies. Strikingly, the incidence of CKD based on medical history was only 17% (15 of the 88 patients), whereas 93% of patients (82 of the 88 patients) showed histopathological features of CKD (Figure 1), such as glomerulosclerosis (46 of the 82 patients), atherosclerosis (75 of the 82 patients), and nephrocalcinosis (4 of the 82 patients). In addition, several patients showed histopathological features compatible with diabetic nephropathy (7 of the 82 patients) or focal segmental glomerulosclerosis (3 of the 82 patients). 4 Our findings suggest that the association between CKD and severe COVID-19 might be even stronger than previously thought.

DISCLOSURE

All the authors declared no competing interests.

ACKNOWLEDGMENT

Availability of Data and Materials

The data underlying this article will be shared upon reasonable request to the corresponding author.

Incidence of CKD and fatal COVID-19 outcome




Figure 1. Incidences of CKD based on medical history and CKD based on renal histology. All patients with a medical history of CKD (15 patients) also had CKD based on renal histology. In contrast, most patients without a medical history of CKD actually did have CKD based on renal histology (67 of the 73 patients). CKD, chronic kidney disease.

Funding

MV and CFMF received a research grant from Baxter Spa, Italy unrelated to the current study.

AUTHOR CONTRIBUTIONS

MV, MvM, and CFMF contributed to the conception and the design of the study. MV, DJ-V, and MvdH contributed to the interpretation of data. MV and DJ-V organized the database. JM made the Figure. MV, DJ-V, MvdH, CFMF, JM, and MvM contributed to the drafting and revising of the article and provided intellectual content of critical importance.

SUPPLEMENTARY MATERIAL

Supplementary File (PDF)

Supplementary References.

- Sorling A, Nordberg P, Hofmann R, Habel H, Svensson P. Association between chronic kidney disease, obesity, cardiometabolic risk factors, and severe COVID-19 outcomes. *Kidney Int Rep.* 2023;8:775–783. https://doi.org/10.1016/j.ekir.2023.01.010
- Kellum JA, Ronco C, Bellomo R. Conceptual advances and evolving terminology in acute kidney disease. *Nat Rev Nephrol*. 2021;17:493–502. https://doi.org/10.1038/s41581-021-00410-w
- Volbeda M, Jou-Valencia D, van den Heuvel MC, et al. Acute and chronic histopathological findings in renal biopsies in COVID-19. Clin Exp Med. 2022:1–12. https://doi.org/10.1007/ s10238-022-00941-x
- Kidney disease improving global outcomes (KDIGO) CKD work group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3:1–150.

Meint Volbeda¹, Daniela Jou-Valencia¹ Marius C. van den Heuvel², Jill Moser^{1,3}, Matijs van Meurs^{1,3} and Casper F.M. Franssen⁴

¹Department of Critical Care, University of Groningen, University Medical Center Groningen, The Netherlands; ²Department of Pathology and Medical Biology, Pathology Section, University of Groningen, University Medical Center Groningen, The Netherlands; ³Department of Pathology and Medical Biology, Medical Biology Section, Laboratory for Endothelial Biomedicine and Vascular Drug Targeting Research, University of Groningen, University Medical Center Groningen, The Netherlands; and ⁴Department of Nephrology, University of Groningen, University Medical Center Groningen, The Netherlands

Correspondence: Meint Volbeda, Department of Critical Care, University of Groningen, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands. E-mail: m.volbeda@umcg.nl

Received 6 April 2023; accepted 10 April 2023

Kidney Int Rep (2023) **8,** 1899–1900; https://doi.org/10.1016/j.ekir.2023.04.032

© 2023 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Response to Letter from Dr. Volbeda and Colleagues Regarding COVID-19 and CKD



The Author Replies: We would like to thank Dr. Volbeda and colleagues for showing interest in our article¹ and for putting our findings in the context of their interesting findings in which a vast majority of patients with severe COVID-19 had histopathological signs of chronic kidney disease (CKD).² We can just agree that CKD is a key risk factor for severe COVID-19 and the main question here is whether milder CKD is underestimated and to a larger extent explains a severe course of COVID-19.

Surely, our study that is based on registered diagnosis from health care episodes in a national patient register underestimates the true prevalence of CKD in particular among those with milder stages of CKD. However, some major differences in study designs should be considered. First, we studied a nationwide sample of patients with severe COVID-19 treated with ventilator in Swedish intensive care units, whereas Volbeda et al. report findings from case series of patients with renal biopsies either with a clinical indication or biopsied postmortem. Therefore, patients with an indication for biopsy (acute kidney injury) or deceased patients were selected, and it is reasonable to assume that their sample is enriched with other risk factors that are shared between CKD and the most severe course of COVID-19. Therefore, the higher prevalence of CKD in the case series could partly be explained by that the deceased were older and had more underlying conditions leading to CKD. In fact, we have recently showed that CKD is not only a risk factor in the population for being admitted to the intensive care unit with severe COVID-19 but also for mortality after admission to the intensive care unit. Most importantly, we can compare characteristics among patients with severe COVID-19 to matched control subjects and report associations between CKD and severe COVID-19 outcomes. Although underestimation of milder CKD by health care diagnosis is likely, this will occur both among patients with COVID-19 and control subjects and is unlikely to affect the relative risk. Although Volbeda et al. suggest that the association between CDK and severe COVID-19 might be stronger, this is an interesting hypothesis, but such a conclusion cannot be supported by data from case series. To study whether the association between histopathological